Method, device, and system to control PH in pulmonary tissue of a subject

• US 20100078020A1
• Filed: 01/08/2009
• Published: 04/01/2010
• Est. Priority Date: 09/30/2008
• Status: Abandoned Application

• Current Assignee: Searete LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Ishikawa, Muriel Y., Wood, Lowell L. JR., Rivet, Dennis J., Hyde, Roderick A., Kare, Jordin T., Wood, Victoria Y.H.
• Application Number:
  US12/319,653
• Publication Number:
  US 20100078020A1
• Time in Patent Office: Days
• US Class Current: 128/203.140
• CPC Class Codes: A61M 11/001 Particle size control
• CPC Class Codes: A61M 11/005 using ultrasonics spraying or atomising liquids using ultrasonic vibrations in general B05B17/06
• CPC Class Codes: A61M 15/0003 with means for dispensing more than one drug
• CPC Class Codes: A61M 15/02 with activated or ionised fluids, e.g. electrohydrodynamic [EHD] or electrostatic devices; Ozone-inhalators with radioactive tagged particles
• CPC Class Codes: A61M 2230/208 pH-value
• CPC Class Codes: A61P 31/12 Antivirals

Abstract

Methods, devices, and systems are provided which include an aerosol generator and a pharmaceutical composition including a membrane selective for a charged ion configured to achieve a selected pH of a pulmonary tissue in a subject. The methods, devices, or systems which include the membrane may be configured to alter selectivity for the charged ion in response to a sensed condition in the pulmonary tissue.

Claims

1. A device comprising:

an aerosol generator, and

a pharmaceutical composition including a membrane selective for a charged ion configured to achieve a selected pH of a pulmonary tissue in a subject.

2. The device of claim 1, wherein the membrane is configured to alter selectivity for the charged ion in response to a sensed condition in the pulmonary tissue.

3. The device of claim 1, wherein the pharmaceutical composition including the membrane is transmitted based upon an existing pH of the pulmonary tissue.

4. The device of claim 1, wherein the charged ion is released based upon an existing pH of the pulmonary tissue.

5. The device of claim 1, wherein membrane integrity is broken based upon an existing pH of the pulmonary tissue.

6. The device of claim 2, further comprising a sensor configured to monitor the sensed condition of the pulmonary tissue from the subject.

7. The device of claim 6, wherein the sensor is configured to monitor at least one of pH of the pulmonary tissue or pH of an exhalant.

8. The device of claim 6, wherein the sensor is configured to monitor at least one of humidity of an exhalant, temperature, breathing rate, peak rate of exhalation, tidal volume, vital capacity, inspiratory capacity, expiratory reserve volume, or residual volume.

9. The device of claim 6, further comprising a controller responsive to the sensor, the controller configured to alter the membrane selectivity for the charged ion.

10. The device of claim 9, wherein the controller is configured to alter a membrane particle size range.

11. The device of claim 9, wherein the controller is configured to selectively deliver one or more membrane particle size ranges.

12. The device of claim 9, wherein the controller is configured to deliver one or more membrane particles of the selected pH.

13. The device of claim 6, wherein the monitoring sensor is in an airway passage of the subject.

14. The device of claim 13, wherein the monitoring sensor is in a sinus or a nostril of the subject.

15. The device of claim 6, wherein the monitoring sensor is integral with the device.

16. The device of claim 1, wherein the membrane selective for the charged ion includes membranes of two or more non-overlapping and distinct particle size ranges configured to contact two or more levels of pulmonary tissue of the subject.

17. The device of claim 16, wherein the two or more distinct and non-overlapping particle size ranges includes powders, micronized microparticles, nanoparticles, or liposomes.

18. The device of claim 16, wherein the membrane selective for the charged ion is an anion exchange particle or a cation exchange particle.

19. The device of claim 16, wherein the membranes selective for the charged ion have an average particle size of less than approximately 10 μ

m.

20. The device of claim 16, wherein the membranes selective for the charged ion have an average particle size of less than approximately 6 μ

m.

21. The device of claim 16, wherein the membranes selective for the charged ion have an average particle size of less than approximately 4 μ

m.

22. The device of claim 16, wherein the membranes selective for the charged ion have an average particle size of less than approximately 2 μ

m.

23. The device of claim 17, wherein the pharmaceutical composition is suitable for administration by dry powder inhalation.

24. The device of claim 1, wherein the membrane is linked to a viral homing entity.

25. The device of claim 24, wherein the viral homing entity binds to a surface molecule of the virus.

26. The device of claim 24, wherein the viral homing entity binds to a cell or tissue of the subject.

27. The device of claim 1, wherein the pulmonary tissue includes an epithelial tissue, mesenchymal tissue, or endothelial tissue.

28. The device of claim 1, wherein the pulmonary tissue includes oropharynx or nasopharynx tissue.

29. The device of claim 1, wherein the pulmonary tissue includes trachial tissue.

30. The device of claim 1, wherein the pulmonary tissue includes bronchial, bronchiole, alveolar duct, or alveoli tissue.

31. The device of claim 1, wherein the aerosol generator includes a vaporizer, nebulizer, or atomizer.

32. The device of claim 1, wherein the charged ion includes a cation.

33. The device of claim 32, wherein the cation includes H⁺, K⁺, or Mg²⁺.

34. The device of claim 1, wherein the charged ion includes an anion.

35. The device of claim 34, wherein the anion includes phosphate, citrate, lactate, pyruvate, or an organic acid.

36. The device of claim 1, wherein the aerosol generator is configured to administer the pharmaceutical composition to the pulmonary tissue of the subject.

37. The device of claim 1, wherein the pharmaceutical composition includes a buffering agent.

38. The device of claim 37, wherein the buffering agent includes at least one of a phosphate buffer, citrate buffer, lactate buffer, pyruvate buffer, or an organic acid buffer.

39. The device of claim 6, further comprising a pH-sensitive detection component in the pharmaceutical composition, the pH-sensitive detection component configured to communicate to the pH-monitoring sensor.

40. The device of claim 39, wherein the pH-sensitive detection component releases a marker indicating a pH range, and the pH-monitoring sensor is configured to recognize the marker.

41. The device of claim 1, wherein the aerosol generator is configured to administer the pharmaceutical composition orally or nasally.

42. The device of claim 1, wherein the aerosol generator administers a continuous or pulsatile dose of the pharmaceutical composition.

43. The device of claim 1, wherein an aerosol dose of the pharmaceutical composition is delivered directly to an individual.

44. The device of claim 1, wherein an aerosol dose of the pharmaceutical composition is delivered to one or more individuals in an enclosed space.

45. The device of claim 1, wherein an aerosol dose of the pharmaceutical composition is delivered through a heating, ventilation, or air conditioning system.

46. The device of claim 1, wherein the pharmaceutical composition is configured to provide a timed-release of the charged ion.

47. The device of claim 1, wherein the pharmaceutical composition is configured to provide a slow-absorbing form of the charged ion.

48. The device of claim 1, wherein the pharmaceutical composition is a liquid or a powder.

49-132. -132. (canceled)